 | • レポートコード：B-MOR-05224 • 出版社/出版日：Mordor Intelligence / 2018年4月 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：Healthcare |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、ヘルスケアナノテクノロジー（ナノ医療）の世界市場について調べ、ヘルスケアナノテクノロジー（ナノ医療）の世界規模、市場動向、市場環境、用途別分析、疾病別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・ヘルスケアナノテクノロジー（ナノ医療）の世界市場インサイト ・ヘルスケアナノテクノロジー（ナノ医療）の世界市場環境 ・ヘルスケアナノテクノロジー（ナノ医療）の世界市場動向 ・ヘルスケアナノテクノロジー（ナノ医療）の世界市場規模 ・ヘルスケアナノテクノロジー（ナノ医療）の世界市場規模：用途別 ・ヘルスケアナノテクノロジー（ナノ医療）の世界市場規模：疾病別 ・ヘルスケアナノテクノロジー（ナノ医療）の世界市場：地域別市場規模・分析 ・ヘルスケアナノテクノロジー（ナノ医療）の北米市場規模・予測 ・ヘルスケアナノテクノロジー（ナノ医療）のアメリカ市場規模・予測 ・ヘルスケアナノテクノロジー（ナノ医療）のヨーロッパ市場規模・予測 ・ヘルスケアナノテクノロジー（ナノ医療）のアジア市場規模・予測 ・ヘルスケアナノテクノロジー（ナノ医療）の日本市場規模・予測 ・ヘルスケアナノテクノロジー（ナノ医療）の中国市場規模・予測 ・ヘルスケアナノテクノロジー（ナノ医療）のインド市場規模・予測 ・ヘルスケアナノテクノロジー（ナノ医療）の韓国市場規模・予測 ・関連企業情報・競争状況 |
The global healthcare nanotechnology market is expected to witness a CAGR of 15.1%. North America currently dominates the market, and is expected to maintain its position over the forecasted period.
Rising Applications in Oncology
Nanomedicine is a promising mode of cancer treatment. With the advantage of the properties of matter at nanoscale, nanomedicine promises to develop innovative drugs with greater efficacy and lesser side effects than standard therapies. Nanoscale objects are used by themselves or as parts of larger devices containing multiple nanoscale objects. It has the potential to change the current methods of diagnosing and treating cancer. Translation of nano-based cancer therapies and diagnostics has witnessed significant progress and several more developments are in the pipeline. The increasing incidence of cancer and importance of nanomedicine in modern cancer treatment procedures, are expected to drive the demand for nanomedicines during the forecast period.
The other factors includes increasing incidence of cardiovascular diseases, increasing research funding and rising awareness of nanomedicine application.
High Costs of Nanotechnology-Based Medical Devices
Cost is the main factor that is often overlooked, which is specifically important in the face of ever increasing healthcare cost and unpredictable reimbursement environment. There are several FDA approved nanoparticle-based products in the market, which can be compared with their non-nanoparticle based counterparts. Although these formulations may be more efficient and less toxic than their counterparts, their costs may also be significantly high. The average cost per dose of anticancer drug doxorubicin is about USD 62-162, compared to USD 5,594 for Doxil, which is a nanoparticle containing doxorubicin. Therefore, owing to the inability of the industry to find a cost-effective method of scaling up the production, the cost of nanomedicine therapies is likely to remain high over the forecast period. This high cost of nanoparticle-assisted medicine is hindering the growth of the market.
The other restraining factor also include time-consuming product approval.
US Dominates the Market
Geographically, the United States currently dominates the market, and is expected to maintain its position over the forecast period. In addition to the booming R&D activities, the United States has also initiated several measures in the recent times, to advance and develop the nanotechnology applications in the healthcare sector. Owing to the large geriatric population, growing need for diagnostics and augmented cancer therapies, government initiatives, and rising awareness of nanomedicines, the US healthcare nanotechnology sector is expected to witness a substantial growth during the forecast period.
Major Players in the Market
The major players are ABBOTT LABORATORIES, COMBIMATRIX CORPORATION, GE HEALTHCARE, SIGMA-TAU PHARMACEUTICALS INC., JOHNSON & JOHNSON, MALLINCKRODT PLC, MERCK & COMPANY INC., NANOSPHERE INC., PFIZER, INC. AND CELGENE CORPORATION amongst others.
Reasons to Purchase this Report
• Current and future healthcare nanotechnology market outlook in the developed and emerging markets
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness fastest growth during the forecast period
• Identify the latest developments, market shares and strategies employed by the major market players.
• 3 months analyst support along with the Market Estimate sheet (in Excel).
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Rising Incidence of Cardiovascular Diseases
6.1.2 Increasing Research Funding
6.1.3 Rising Awareness of Nanomedicine Application
6.1.4 Increasing Applications in Oncology
6.2 Market Restraints
6.2.1 High Costs of Nanotechnology-Based Medical Devices
6.2.2 Time-Consuming Product Approval
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 Segmentation-By Applications
7.1.1 Drug Delivery
7.1.2 Drugs
7.1.3 Biomaterials
7.1.4 Active Implants
7.1.5 In-Vitro Diagnostic
7.1.6 In-Vivo Imaging
7.2 By Disease
7.2.1 Neurological Diseases
7.2.2 Cardiovascuar Diseases
7.2.3 Oncology
7.2.4 Disposable IVD Devices
7.2.5 Anti-Inflammatory
7.2.6 Anti-Infective
7.2.7 Others
7.3 Segmentation-By Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia & New Zealand
7.3.3.5 South Korea
7.3.3.6 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of the Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Abbott Laboratories
9.2 Combimatrix Corporation
9.3 Ge Healthcare
9.4 Sigma-Tau Pharmaceuticals, Inc.
9.5 Johnson & Johnson
9.6 Mallinckrodt Plc
9.7 Merck & Company, Inc.
9.8 Nanosphere, Inc.
9.9 Pfizer, Inc.
9.10 Celgene Corporation
9.11 List Not Exhaustive
10. Future of the Market